尤瑞克林联合拜阿司匹林治疗脑梗死疗效研究

摘要

目的：观察尤瑞克林联合拜阿司匹林治疗脑梗死的疗效。方法治疗组、对照组均同时予以药物治疗。治疗组予尤瑞克林+拜阿司匹林,对照组予拜阿司匹林；在治疗开始、第14天和第28天进行神经功能缺损程度(Chi-nese Stroke Scale,CSS)、改良巴氏指数(Modified Barthel Index ,MBI)、简式Fugal-Meyer运动评分(Fugal-Meyer Assessment,FMA)比较。结果第14天治疗组MBI改善优于对照组,第28天治疗组CSS、MBI、FMA改善情况好于对照组；第14天、第28天治疗组疗效好于对照组。结论尤瑞克林联合拜阿司匹林治疗脑梗死疗效确切,值得临床推广。%Objective To assess the effects of Urinary Kallid inogenase combined with Asprin for cerebral infarction patients. Methods All the patiens received Asprin treatment,while patients in study group received Urinary Kallidino-genase through injection additionally,the control growp received Asprin Chinese Stroke Scale (CSS)、Modified Barthel Index (MBI) and Fugal-Meyer Assessment (FMA) were used to evaluate clinical conditions. Results Scores of CSS, MBI and FMA showed clinical improvement after 14 or 28 days in each subgroups. In the study group, MBI scores were significantly higher than that in control group after 14 days,while CSS,MBI and FMA scores in study group were statistically improved than that of control group 28 days later. Urinary Kallid inogenase combined with asprin showed better clinical outcomes in the patients with cerebral infarction. Conclusion Urinary Kallidinogenase combined with Asprin can increase the clinical effectiveness,reduce the rate of disability and improve the quality of life for cerebral infarction patiens.